We start this week's episode by discussing access to investigational COVID-19 vaccines and recapping the problems with the ADAURA study. We transition from there to a Question of the Week with medical student Audrey Tran of Oregon Health & Science University. Finally, we introduce a new segment - Journal Club with a Fellow. In this inaugural segment we invite Dr. Karine Tawagi of the Oschner Clinic in Louisiana to the podcast to talk about IMbrave150.

This is the recording of a LIVE episode of Plenary Session in which Dr. Sue S Yom interviewed our host, Dr. Vinay Prasad, on how he built his career and how he conceptualizes his work. There's also a surprise guest near the end! Thank you to Dr. Kaleigh Doke, Dr. Brian Kavanagh, and the Virtual Visiting Professor Network for hosting this special episode.

This week we respond to several questions sent in by listeners and then we interview Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada on MedTwitter, other recent events, and his recently published paper titled "Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials".

This week we discuss two major papers: The first was just recently released in Nature and it's titled "The National Lung Matrix Trial of personalized therapy in lung cancer". The second is a few years old, but exemplifies the importance of trial design. We discuss the second paper, titled "A Randomized Trial of Intensive versus Standard Blood-Pressure Control" and published in the New England Journal of Medicine with Dr. Mark Friedberg, a health policies and performance measurement researcher.

This week's BONUS episode is a discussion of the National Clinician Scholars Program with Dr. Hilary Seligman, the head of the program at University of California, San Francisco. The deadline for the application for the 2021-2023 cohort is July 15, 2020 (very soon!), though there may be some leniency due to the pandemic.

This week we discuss recent research (and the accompanying Twitter thread) on the risk of COVID-19 among users of proton pump inhibitors (PPIs). We also hold a philosophical discussion on the research surrounding time to treatment initiation (TTI) in cancer medicine. We end the episode with an interview with Dr. Lynora Saxinger of the University of Alberta, Edmonton, a specialist in Infectious Diseases.

This BONUS episode is the recording of a lecture given on June 18, 2020 as part of Stanford's METRICS International Forum. METRICS stands for Meta-Research Innovation Center at Stanford University. This lecture is geared towards a broad audience and aims to provide a general sense of current cancer research. The lecture is titled "Cancer Meta-Research 101".

This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology. Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal of Clinical Oncology: Precision Oncology, titled "Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program".

This week we briefly cover updates on the RECOVERY trial before segueing into an interview with Dr. Andrae Vandross on Twitter (specifically #medtwitter), academic discussions, and changing your career to find your calling.

This week's episode is jam-packed with topics! We talk about the RECOVERY trial, the U.S. clinical trial infrastructure, event-free survival (EFS) and cost of care in acute myeloid leukemia, how long it takes to write papers in academic medicine, threats to public health officials, and the application to medicine of Dr. Raj Chetty's work in economics. Finally, we interview this week's special guest, Dr. Ian Tannock, on docetaxel, prostrate cancer, clinical trial appraisal, and his career in medicine.

This week we tackle the topic of tucatinib in HER2-positive breast cancer with brain metastases. We also interview Dr. Cailin O'Connor of the University of California Irvine on her research on misinformation and disinformation. We discuss her recent article in the Boston Review, titled "Hydroxychloroquine and the Political Polarization of Science", as well as her extensive body of work.

We start this week's episode by covering some recent research: After thoroughly critiquing the recent randomized trial of hydroxychloroquine for postexposure prophylaxis for COVID-19, we then discuss the five abstracts selected for plenary sessions at the recent virtual meeting of the American Society of Clinical Oncology. We transition from there to a Question from a Medical Student with Audrey Tran of Oregon Health & Science University on the recent decision to make the USMLE Step 1 exam pass/fail. Finally, we end with an interview with Dr. Jane Zhu, also of OHSU, on her current research and her new paper published in JAMA titled, "Private Equity Acquisitions of Physician Medical Groups Across Specialties, 2013-2016". Dr. Zhu first guest-starred on Plenary Session in episode 1.31.

This week we talk all things COVID-19! We start with an in-depth Classical Hematology Chat with Dr. Sven Olson and Dr. Joseph Shatzel of Oregon Health & Science University on thrombosis and anticoagulation in COVID-19, touching on a number of recent studies. We then turn to a conversation with Dr. Walid Gellad of the University of Pittsburgh on new pharmaceutical treatments for COVID-19.

This week we discuss why being open-minded enough to agree partially with someone - instead of taking an all-or-nothing approach to a discourse - is important. We also sit down with epidemiologist Dr. Daniel Morgan of the University of Maryland School of Medicine to critique the public health policy concerning COVID-19 transmission.

This week we have an announcement -- the audiobook of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer", written and narrated by our host Vinay Prasad, is available now on Amazon, iTunes, and Audible! We also have an in-depth journal club for you on the findings of the PROfound trial as published in a new paper out in the New England Journal of Medicine titled "Olaparib for Metastatic Castration-Resistant Prostate Cancer".

Finally, we end the episode with an interview with Dr. Adam Cifu of the University of Chicago on literature, medicine, maintaining a feeling of normalcy and self during COVID-19, and more!

This week's topic is all things COVID-19 -- we discuss the viral scandal of British epidemiologist Neil Ferguson's actions and how it reflects (or doesn't) on his work, we talk about the nuances of how to end lockdowns, and we bring back Dr. Benjamin Singer, a pulmonary and critical care physician at Northwestern University, to address updates in the ICU management of COVID-19.

This week we begin with a monologue on the recent controversy surrounding Dr. John Ioannidis's published opinions on the COVID-19 pandemic. We end with a group discussion with Oregon Health & Science University's Hematology/Oncology fellows on our host's, Vinay Prasad's, new book "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer.

This week we start with an in-depth monologue on various new developments surrounding COVID-19, specifically the new study in NEJM on the compassionate use of remdesivir as well as the CDC's advice for the general public to wear cloth masks. We end with an interview with Dr. Ameet Sarpatwari of Harvard Medical School on how to create a more effective pharmaceutical system, the CREATES Act of 2019, developing fair and equitable drugs to treat COVID-19, and how to create a just system that balances the need for innovation with the need for access. Dr. Ameet Sarpatwari is the Assistant Director of PORTAL.

This week we have a far-reaching monologue on COVID-19 and how people are reacting to the public health recommendations concerning COVID-19 (such as cancelling conferences and school, maintaining 6+ feet of distance, wearing cloth masks). We end with an insightful interview with Dr. Venk Murthy on polygenic risk score and, at the end, a bit about how the world of science is failing to combat hype.

This week we discuss several recent articles on the novel coronavirus (SARS-CoV-2) and COVID-19, specifically Dr. Siddhartha Mukherjee's article on the history and science of humanity's history with viruses, Dr. Ezekiel Emanuel's essay on how to fairly allocate dwindling medical resources during this global pandemic, and Dr. John Ioannidis's article on the "evidence fiasco" that has been our response to COVID-19. We end the episode with a Classical Hematology Chat with Drs. Sven Olson and Joseph Shatzel.